2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1632 A phase 1 study of the menin inhibitor ziftomenib in combination with the cereblon E3 ligase modulator mezigdomide in relapsed or refractory KMT2A-rearranged or NPM1-mutant acute myeloid leukemia

Wallace A. Bourgeois, MD, Michelle Hyunju Lee, MD2, Brandon James Aubrey, MBBS PhD FRACP FRCPA3, Julia Keating, M.S.4, Andrew M Brunner, MD5, Gabriela Soriano Hobbs, MD6, Philip Amrein, MD7, Hanno Hock, MD, PhD8, Rupa Narayan, MD9, Marlise Rachael Luskin, MD, MSCE10, Evan C. Chen, MD11, Shai Shimony, MD, MPH12, Eric Stephen Winer, MD13, Jacqueline S. Garcia, MD14, Jessica A. Pollard I, MD15, Andrew A. Lane, MD, PhD16, Daniel J DeAngelo, MD, PhD17, Richard Stone, MD18, Amir T. Fathi, MD19
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
7 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
9 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States

Background and Significance:

Menin inhibitors have demonstrated promising activity for patients with relapsed or refractory (R/R) KMT2A-rearranged (KMT2A-r) and NPM1-mutant (NPM1m) acute myeloid leukemia (AML). Revumenib is Food and Drug Administration-approved for R/R KMT2A-r and NPM1m AML after demonstrating complete remission (CR) or CR with partial hematologic recovery (CRh) rates of ~23% for KMT2A-r acute leukemia (Issa et al, JCO, 2025) and NPM1m AML (Arellano et al, Blood, 2025). Ziftomenib is approved for R/R NPM1m AML, having demonstrated CR/CRh rates of 22% for R/R NPM1m AML (Wang et al, JCO, 2025). However, durable single-agent responses are limited, and acquired MEN1 mutations impacting menin inhibitor activity have been reported with revumenib (Perner et al, Nature, 2023). Combinations that deepen responses and prevent or overcome resistance are needed.

 

Prior work demonstrated that Ikaros degradation with IMiD- and CELMoD-class molecular glues synergizes with menin inhibition in KMT2A-r and NPM1m AML models and enhances antileukemic activity, including induction of apoptosis (Aubrey et al, Nat Cancer, 2022). Mezigdomide, which exhibits more potent Ikaros degradation, showed superior single-agent activity and synergized with revumenib in KMT2A-r and NPM1m patient-derived xenograft (PDX) models, including a PDX model derived from a patient whose leukemia had acquired a MEN1 mutation (Bourgeois et al, Blood, 2024). Mezigdomide-containing combination therapy has completed a phase 3 trial in multiple myeloma (Dimopoulos et al, Lancet 2026). These data support a phase 1 trial of mezigdomide plus ziftomenib in R/R KMT2A-r or NPM1m AML, including patients previously treated with a menin inhibitor.

 

Study Design and Methods:

This is a prospective, open-label, phase 1 dose-escalation and expansion study (NCT07355335) conducted across the Dana-Farber/Harvard Cancer Center consortium (Massachusetts General Hospital, coordinating center; Dana-Farber Cancer Institute; Boston Children's Hospital). Key inclusion criteria include patients ≥16 years during the dose escalation phase and >12 years during the dose expansion phase, weight ≥40 kg, a diagnosis of R/R KMT2A-r or NPM1m AML after ≥1 prior line of therapy, ≥5% bone marrow blasts, adequate organ/marrow function, and ECOG ≤2 or Karnofsky/Lansky ≥50. Prior menin inhibitor therapy is permitted. Key exclusion criteria include NPM1m AML with FLT3-ITD allelic ratio ≥0.05, active CNS disease, QTcF >480 ms, hematopoietic stem cell transplant within 90 days or clinically significant graft-versus-host-disease.

 

A traditional 3+3 design will determine the recommended phase 2 dose (RP2D) of mezigdomide in combination with ziftomenib at 600 mg/day, the FDA-approved dose for R/R NPM1m AML, for up to 12 cycles. Mezigdomide will initially be administered at 0.6 mg daily on days 1-21 of each 28-day cycle, with de-escalation to 0.6 mg on days 1-14 or escalation to 1.0 mg on days 1-21 across three planned dose levels. Dose-limiting toxicities (DLTs) will be assessed during Cycle 1. Following RP2D determination, an expansion cohort of 6-12 patients will be enrolled (maximum 24 patients total). Excess toxicity in the expansion cohort will be monitored using a Bayesian method over the first four cycles. Estimated accrual duration is 18 months, with the first patient enrollment anticipated in the third quarter of 2026.

 

The primary objectives are to evaluate the safety and tolerability of mezigdomide plus ziftomenib and determine the RP2D of mezigdomide when combined with ziftomenib. Secondary endpoints include CR/CRh rate and overall response rate after up to 12 cycles and estimation of 2-year overall and relapse-free survival. Response rates will be summarized with exact binomial 90% confidence intervals, and survival endpoints will be estimated using Kaplan-Meier methods.

Wallace A. Bourgeois, MD: No relevant conflicts of interest to declare.